Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

NAD⁺ precursors and EGCG may increase hair density, but users report mixed results with no significant hair gains. Some users suggest combining these with finasteride or dutasteride for better results.

Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.

Topical dutasteride 0.05% is more effective for hair growth than oral finasteride 1mg, with minimal DHT reduction. The formulation uses castor oil and MCTs for better absorption but is not widely available until 2028.

A user discusses their extensive hair loss treatment regimen, which includes dutasteride, oral and topical minoxidil, RU58841, various supplements, and lifestyle changes. The conversation includes opinions on the effectiveness and necessity of such a comprehensive approach, with some users suggesting alternatives like microneedling and questioning the high dosage of dutasteride.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

The conversation discusses hair shedding while using 0.5 mg dutasteride daily for 8.5 months, with users sharing experiences of shedding various hair lengths and thicknesses. It is suggested that shedding can be part of the hair cycle synchronization and may not indicate worsening hair loss.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

The user shared progress pictures after using topical dutasteride for 4 months, experiencing heavy shedding at month 2, which returned to baseline 1.5 months ago. Previous treatments with topical and oral finasteride and minoxidil were ineffective or caused side effects, and the user is hopeful about the shedding phase indicating potential effectiveness of topical dutasteride.

Nicotine use, especially from vaping, may worsen hair shedding and reduce the effectiveness of finasteride and dutasteride. Quitting nicotine seems to improve hair health.

A user with diffuse hair loss after taking accutane, which might have triggered genetic predisposition to AGA; their experience taking finasteride and experiencing side effects of increased oil production, increased sex drive, worsening hair texture; they are considering zinc supplementation with finasteride or other treatments such as alfatradiol or spironolactone.

Lichen Planopilaris (LPP) is an autoimmune condition causing permanent hair loss and fibrosis, often misdiagnosed. Treatments include pioglitazone, topical corticosteroids, anti-inflammatory medication, and Jak inhibitors.

CB 03 01 (Breezula) was tried for hair loss but showed no significant improvement, with issues in dissolving and application. Finasteride and dutasteride remain the most effective treatments, while minoxidil is also used; CB's effectiveness is questioned, and topical alternatives like bicalutamide are considered.

Dutasteride users report mixed results, with some experiencing shedding and others seeing no improvement or hair regrowth. Many users also discuss using finasteride and minoxidil, with some preferring topical treatments for better results.

A user is making their own dutasteride solution using MCT oil but is concerned about its effectiveness and bioavailability. They are considering using propylene glycol or adding ethanol for better results, while others suggest the current dosage might be excessive.

Creatine use with finasteride has mixed effects on hair, with some experiencing shedding and others noticing no impact. Many attribute concerns to individual sensitivity or unrelated factors.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

Users discussed the effectiveness of Everychem's solution, similar to PP405, with some reporting improved hair thickness and new growth. Concerns were raised about safety and the legitimacy of the product, with some users advising against purchasing research chemicals.

The user experienced a sudden decrease in hair density after starting alfatradiol while already using finasteride. Another user mentioned that initial shedding can occur with hair loss treatments, but it may not last long.

The user had a hair transplant in March 2025 and has been using finasteride since 2023, which halted hair loss but didn't fully restore density. They plan to use dutasteride twice weekly, finasteride five times a week, and saw palmetto to improve hair thickness.

User experienced hair thickening with pyri but also side effects like reduced sex drive. Stopping pyri and returning to CB restored sex drive, suggesting pyri may go systemic or be incorrectly formulated.

PP405 may not need daily use like minoxidil, but finasteride might still be needed to maintain hair regrowth. PP405 reawakens dormant hair follicles, potentially offering a long-term solution, though not a permanent cure.

A user experiencing diffuse thinning at the hairline after 12 months on finasteride is considering adding minoxidil, dutasteride, or RU58841 to their treatment. Another user suggests adding minoxidil now, holding off on dutasteride, and shares personal side effects from RU58841.

A person has been using finasteride, minoxidil, OM, dutasteride, and RU58841 for hair loss for various durations but is still experiencing constant shedding and thinning. Suggestions from others include checking for potential nutritional deficiencies.

The user has been using topical minoxidil for over a year and added kx826/pyrilutamide to improve hair growth, avoiding finasteride due to side effects like lowered libido and panic attacks. They report positive results with reduced shedding and healthier hair, particularly in areas previously unresponsive to minoxidil.

Epristeride is a selective 5 alpha reductase type 2 inhibitor that may reduce scalp DHT similarly to finasteride, with potentially fewer side effects. It is suggested that combining epristeride with finasteride or dutasteride could enhance hair loss treatment effectiveness.

Lab-grown hair using iPSCs is being explored, but practical applications are limited. Finasteride is suggested as the only current effective treatment.

A user experienced significant hair density increase after 80 days using oral finasteride, topical minoxidil, and microneedling with a derma pen. They reported minimal side effects and attributed their success to being a hyper responder to the treatments.

A user experienced rapid hair loss despite taking finasteride 1mg and undergoing PRP treatment. They also take a supplement with biotin, iron, zinc, and calcium but have not seen improvement.

The conversation discusses using 2.5mg dutasteride, 0.5mg dutasteride with topical treatments, and other combinations like oral minoxidil, RU58841, and microneedling for male pattern baldness. Users share experiences and suggest various treatment regimens, emphasizing the effectiveness of dutasteride and minoxidil.

Keratin microspheres may offer additional mechanisms to combat hair loss compared to minoxidil. The process to create these microspheres is relatively simple and can be done at home with basic equipment.